TNF Alpha Inhibitors Global Market Report 2023

Quick Summary:

In the evolving landscape of the pharmaceutical industry, a solid understanding of the TNF alpha inhibitors market is crucial for strategic decision-making. As such, the potential clinical advances driven by these representatives of biologic drugs are paramount. This appealing sector, comprising sales of medications such as infliximab, adalimumab, etanercept, golimumab, and certolizumab, is poised for robust growth, natural victims of the aggression of inflammatory diseases can find solace within the arms of these highly effective suppressors.

By acquiring our market research report, you gain a comprehensive understanding of the TNF alpha inhibitors market. Our lucid document fairly represents the current market situation, unprecedented market dynamics and potential future trends. It meticulously highlights the boundaries and opportunities that are shaping the market, keeping you ahead of the competition by enabling informed decision-making. Remember, these medications - though not without their potential side effects - offer promising outcomes in the battle against damaging inflammatory diseases. Insights from our thorough research are essential guideway in this buoyant market.

The global TNF alpha inhibitors market is expected to grow from $38.56 billion in 2021 to $40.73 billion in 2022 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services effecting many markets across the globe. The TNF alpha inhibitors market is expected to reach $43.83 billion in 2026 at a CAGR of 1.9%.

The TNF alpha inhibitors market consists of sales of infliximab, adalimumab, etanercept, golimumab, and certolizumab. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

TNF alpha inhibitors refer to medications that are used to treat inflammatory diseases such rheumatoid arthritis (RA), psoriatic arthritis, and juvenile idiopathic arthritis and that help to reduce or eliminate inflammation. TNF inhibotrs may have a higher risk for skin cancer, especially non-melanoma skin cancers such as squamous cell carcinoma.

The main types of drugs in TNF alpha inhibitors are remicade (infliximab), enbrel (etanercept), humira (adalimumab), and cimzia (certolizumab pegol), and simponi (golimumab). REMICADE is a prescription drug for persons with slightly too severely active Crohn's disease who haven't had success with other treatments. The different routes of administration include oral, subcutaneous, intravenous, and others and involve various types of diseases such as inflammatory bowel disease, psoriatic arthritis, ulcerative colitis (UC), rheumatoid arthritis, and ankylosing spondylitis, and others.

The growing prevalence of inflammatory diseases such as inflammatory bowel disease and psoriasis is a key factor driving the growth of the TNF alpha inhibitors market. Tumor necrosis factor-alpha (TNF alpha) inhibitors are commonly used in gastroenterology, dermatology, and rheumatology for the treatment of various immune-mediated inflammatory diseases. Globally, the prevalence of inflammatory bowel disease (IBD) is about 0.5-24.5 cases for ulcerative colitis per 100,000 person-years and 0.1-16 cases for Crohn's disease per 100,000 person-years, and overall, IBD prevalence is 396 cases per 100,000 people each year. Thus, the increasing number of cases of inflammatory diseases increases the demand for TNF alpha inhibitors contributing to the growth of the market.

The adverse side effects of TNF alpha inhibitors on patients are expected to limit the growth of the TNF alpha inhibitors market. The multiple adverse effects of TNF alpha inhibition identified by clinical trials and post-marketing surveillance include injection site reactions, neutropenia, infusion reactions, and infections. According to the U.S. Food and Drug Administration (FDA), TNA alpha inhibitors can cause serious infections in people with weaker immune systems or low resistance levels. The infections can be bacterial, mycobacterial, fungal, and viral leading to various diseases such as tuberculosis, histoplasmosis, candidiasis, blastomycosis, and hepatitis B. These side effects force patients to prefer alternatives such as non-TNF biologics, which hampers the growth of the market.

In May 2020, AbbVie Inc, a US-based biopharmaceutical company, completed the acquisition of Allergan plc for an amount of $63 billion. The acquisition is expected to expand and diversify AbbVie Inc’s revenue base and its existing immunology portfolio. Allergan plc is an Ireland-based pharmaceutical company engaged in manufacturing and marketing drugs and medical devices in the areas of the central nervous system, eye care, medical aesthetics, and gastroenterology.

The regions covered in the TNF alpha inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the TNF alpha inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from goods and/or services sold within the specified market and geography through sales, grants, or donations in terms of currency (in USD ($) unless otherwise specified).

The revenues for a specified geography are consumption values - that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced. It does not include revenues from resales either further along the supply chain or as part of other products.

The TNF alpha inhibitors market research report is one of a series of new reports that provides TNF alpha inhibitors market statistics, including TNF alpha inhibitors industry global market size, regional shares, competitors with a TNF alpha inhibitors market share, detailed TNF alpha inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the TNF alpha inhibitors industry. This TNF alpha inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Major players in the TNF alpha inhibitors market are AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A, Novartis International AG, Pfizer Inc., Merck & co. Inc., Janssen Biotech, Ablynx, and Momenta Pharmaceuticals.

This product will be delivered within 1-3 business days.

Frequently Asked Questions about the Global TNF Alpha Inhibitors Market

What is the estimated value of the Global TNF Alpha Inhibitors Market?

The Global TNF Alpha Inhibitors Market was estimated to be valued at $40.73 billion in 2022.

What is the growth rate of the Global TNF Alpha Inhibitors Market?

The growth rate of the Global TNF Alpha Inhibitors Market is 1.9%, with an estimated value of $43.83 billion by 2026.

What is the forecasted size of the Global TNF Alpha Inhibitors Market?

The Global TNF Alpha Inhibitors Market is estimated to be worth $43.83 billion by 2026.

Who are the key companies in the Global TNF Alpha Inhibitors Market?

Key companies in the Global TNF Alpha Inhibitors Market include AbbVie Inc., Amgen Inc., Johnson & Johnson Services Inc., UCB S.A, Novartis International AG, Pfizer Inc., Merck & co. Inc., Janssen Biotech, Ablynx and Momenta Pharmaceuticals.

Report Attribute	Details
No. of Pages	250
Published	February 2023
Forecast Period	2022 - 2026
Estimated Market Value ( USD ) in 2022	$ 40.73 billion
Forecasted Market Value ( USD ) by 2026	$ 43.83 billion
Compound Annual Growth Rate	1.9%
Regions Covered	Global

1. Executive Summary

2. TNF Alpha Inhibitors Market Characteristics

3. TNF Alpha Inhibitors Market Trends And Strategies

4. TNF Alpha Inhibitors Market - Macro Economic Scenario
4.1 COVID-19 Impact On TNF Alpha Inhibitors Market
4.2 Ukraine-Russia War Impact On TNF Alpha Inhibitors Market
4.3 Impact Of High Inflation On TNF Alpha Inhibitors Market

5. TNF Alpha Inhibitors Market Size And Growth
5.1. Global TNF Alpha Inhibitors Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global TNF Alpha Inhibitors Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market

6. TNF Alpha Inhibitors Market Segmentation
6.1. Global TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

Remicade (infliximab)
Enbrel (etanercept)
Humira (adalimumab)
Cimzia (certolizumab pegol)
Simponi (golimumab)

6.2. Global TNF Alpha Inhibitors Market, Segmentation By Route of Administration, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

Oral
Subcutaneous
Intravenous
Others

6.3. Global TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

Inflammatory Bowel Disease
Psoriatic Arthritis
Ulcerative Colitis (UC)
Rheumatoid Arthritis
Ankylosing Spondylitis
Others

7. TNF Alpha Inhibitors Market Regional And Country Analysis
7.1. Global TNF Alpha Inhibitors Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global TNF Alpha Inhibitors Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific TNF Alpha Inhibitors Market
8.1. Asia-Pacific TNF Alpha Inhibitors Market Overview

Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.3. Asia-Pacific TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China TNF Alpha Inhibitors Market
9.1. China TNF Alpha Inhibitors Market Overview
9.2. China TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.3. China TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India TNF Alpha Inhibitors Market
10.1. India TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.2. India TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan TNF Alpha Inhibitors Market
11.1. Japan TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.2. Japan TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia TNF Alpha Inhibitors Market
12.1. Australia TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.2. Australia TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia TNF Alpha Inhibitors Market
13.1. Indonesia TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.2. Indonesia TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea TNF Alpha Inhibitors Market
14.1. South Korea TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.2. South Korea TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe TNF Alpha Inhibitors Market
15.1. Western Europe TNF Alpha Inhibitors Market Overview
15.2. Western Europe TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.3. Western Europe TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK TNF Alpha Inhibitors Market
16.1. UK TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.2. UK TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany TNF Alpha Inhibitors Market
17.1. Germany TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.2. Germany TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France TNF Alpha Inhibitors Market
18.1. France TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.2. France TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe TNF Alpha Inhibitors Market
19.1. Eastern Europe TNF Alpha Inhibitors Market Overview
19.2. Eastern Europe TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.3. Eastern Europe TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia TNF Alpha Inhibitors Market
20.1. Russia TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.2. Russia TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America TNF Alpha Inhibitors Market
21.1. North America TNF Alpha Inhibitors Market Overview
21.2. North America TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.3. North America TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA TNF Alpha Inhibitors Market
22.1. USA TNF Alpha Inhibitors Market Overview
22.2. USA TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.3. USA TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America TNF Alpha Inhibitors Market
23.1. South America TNF Alpha Inhibitors Market Overview
23.2. South America TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.3. South America TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil TNF Alpha Inhibitors Market
24.1. Brazil TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.2. Brazil TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East TNF Alpha Inhibitors Market
25.1. Middle East TNF Alpha Inhibitors Market Overview
25.2. Middle East TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.3. Middle East TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa TNF Alpha Inhibitors Market
26.1. Africa TNF Alpha Inhibitors Market Overview
26.2. Africa TNF Alpha Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.3. Africa TNF Alpha Inhibitors Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. TNF Alpha Inhibitors Market Competitive Landscape And Company Profiles
27.1. TNF Alpha Inhibitors Market Competitive Landscape
27.2. TNF Alpha Inhibitors Market Company Profiles
27.2.1. AbbVie Inc.
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Amgen Inc.
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Johnson & Johnson Services, Inc.
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. UCB S.A
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Novartis International AG
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance

28. TNF Alpha Inhibitors Pipeline Analysis

29. Key Mergers And Acquisitions In The TNF Alpha Inhibitors Market

30. TNF Alpha Inhibitors Market Future Outlook and Potential Analysis

31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Historic And Forecast Inflation Rates
31.4. Research Inquiries
31.5. About the Publisher
31.6. Copyright And Disclaimer

Executive Summary

TNF Alpha Inhibitors Global Market Report 2023 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tnf alpha inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Where is the largest and fastest growing market for tnf alpha inhibitors? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tnf alpha inhibitors market global report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

Scope

Markets Covered

1) By Drug: Remicade (Infliximab); Enbrel (Etanercept); Humira (Adalimumab); Cimzia (Certolizumab Pegol); Simponi (Golimumab)
2) By Route Of Administration: Oral; Subcutaneous; Intravenous; Other Route Of Administration
3) By Disease Type: Inflammatory Bowel Disease; Psoriatic Arthritis; Ulcerative Colitis (UC); Rheumatoid Arthritis; Ankylosing Spondylitis; Other Disease Types

Companies Mentioned: AbbVie Inc.; Amgen Inc.; Johnson & Johnson Services Inc.; UCB S.A; Novartis International AG

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.